ArticleClinical rheumatology2026
Association between sarcopenia and mortality in patients with osteoarthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia and osteoarthritis (OA) frequently coexist, yet the correlation of sarcopenia with mortality specifically within the OA population remains unclear. We intend to shed light on the correlation of sarcopenia and all-cause/cardiovascular disease (CVD) mortality in OA patients.
methodsWe included 1301 OA individuals from National Health and Nutrition Examination Survey (NHANES) 1999-2018. Sarcopenia was determined utilizing appendicular skeletal muscle mass from dual-energy X-ray absorptiometry and body mass index. All-cause and CVD mortality were confirmed by connection with the national death index until December 31, 2019. Survival probabilities were evaluated via log-rank test, and the linkage of sarcopenia and mortality was evaluated by multivariable Cox regression.
resultsAmong the 1301 participants, 240 (18.4%) have been diagnosed with sarcopenia. Survival analysis demonstrated significantly reduced survival probabilities for individuals with sarcopenia compared to those without (log-rank P < 0.001). In the fully adjusted Cox models, sarcopenia was connected to higher all-cause mortality (HR = 1.880, 95% CI 1.387-2.548) and CVD mortality (HR = 1.942, 95% CI 1.054-3.578).
conclusionElevated all-cause and CVD mortality correlate with sarcopenia in patients with OA. Sarcopenia screening potentially facilitates a more thorough evaluation of survival for this population. Future research should clarify how dynamic transitions in sarcopenia status relate to survival outcomes over time. Key Points • Sarcopenia is associated with elevated all-cause and cardiovascular disease mortality in patients with osteoarthritis. • Identifying sarcopenia may provide valid prognostic information for the osteoarthritis population.
Indexed as
Identifiers
41917540What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.